Clinical efficacy of the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP) in the treatment of feline immunodeficiency virus-infected cats.
In in vitro studies, the acyclic nucleoside phosphonate 9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine (PMPDAP) inhibited the replication of feline immunodeficiency virus (FIV). No information about its clinical efficacy is available so far. The aim of this prospective placebo-controlled, double-blinded study was to evaluate the antiviral efficacy of PMPDAP in cats naturally infected with FIV. Twenty cats were randomly assigned to two treatment groups receiving either PMPDAP (25 mg/kg) or placebo twice per week subcutaneously for 6 weeks. The general health status (Karnofsky's score), clinical signs, laboratory, immunological, and surrogate parameters were evaluated. No significant differences were found between PMPDAP- and placebo-treated cats, although cats treated with PMPDAP showed a tendency for improvement in their Karnofsky's score and clinical signs. Haematological side effects were noted in the PMPDAP-treated cats. Thus, PMPDAP may be an option in treating cats if it becomes available for veterinarians, but side effects have been monitored.
Clinic for Small Animal Medicine, Ludwig Maximilian University, Munich, Germany.
Anja D
AD
Hartmann
Natalie
N
Wilhelm
Jan
J
Balzarini
Katrin
K
Hartmann
D000225:Adenine / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001708:Biopterins / Q000097:blood; D016516:CD4-CD8 Ratio; D002415:Cats; D004311:Double-Blind Method; D016181:Feline Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000821:virology; D005260:Female; D016089:Immunodeficiency Virus, Feline / Q000187:drug effects*; D007279:Injections, Subcutaneous / Q000662:veterinary; D017567:Karnofsky Performance Status; D008297:Male; D009943:Organophosphorus Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D011446:Prospective Studies; D016896:Treatment Outcome; D014976:Xanthopterin / Q000097:blood
C090125:9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine; D000998:Antiviral Agents; D009943:Organophosphorus Compounds; D001708:Biopterins; D000225:Adenine; D014976:Xanthopterin